Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting

ABSTRACTAccording to recent research, bispecific antibodies (BsAbs) are a promising new immunotherapy method. Various BsAb forms are constantly being developed. In the year 2022 alone, four BsAbs (tebentafusp, faricimab, mosunetuzumab, and teclistamab) were approved for clinical applications. BsAbs including odronextamab, talquetamab, linvoseltamab, and elranatamab are being actively evaluated in different clinical studies. Preliminary results show promising response rates in relapsed/refractory follicular lymphoma (RRFL), relapsed/refractory diffuse large B-cell lymphoma (RRDLBCL), and relapsed/refractory multiple myeloma (RRMM), especially in heavily pretreated patients, including those who have progressed after proteasome inhibitors, immunomodulatory drugs, anti-CD38 antibodies, and CAR-T therapies. We summarized data published at the 28th European Hematology Association (EHA) annual meeting, which was held in Frankfurt between 8 June 2023 and 11 June 2023 on BsAbs monotherapy or combination therapy for RRFL, RRDLBCL, and RRMM.KEYWORDS: Bispecific antibodiesfollicular lymphomadiffuse large B-cell lymphomamultiple myelomaimmunotherapy Declaration of interestThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Reviewer disclosuresPeer reviewers on this manuscript have no relevant financial or other relationships to disclose.Author contribution statementJ Yu designed and directed the manuscript. X Li, P Zhang and H Sun wrote the manuscript draft. L Han, Z Jiang and J Yu reviewed the manuscript. Z Jiang provided resources. All authors reviewed and approved the final manuscript.AcknowledgmentsThe authors would like to thank all the patients and their families for participating in clinical trials testing the drugs mentioned in this review.Additional informationFundingThis paper was funded by the Science and Technology Department of Henan Province project number LHGJ20190039, SBGJ20202076, Zhengzhou Municipal Science and Technology Bureau project number XTCX2023010, and Talent Research Fund of the First Affiliated Hospital of Zhengzhou University, granted to J Yu.